Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Revenue of Nektar Therapeutics (NKTR)
Revenue in 2023 (TTM): $90.12 M
According to Nektar Therapeutics's latest financial reports the company's current revenue (TTM) is $90.12 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Nektar Therapeutics
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $90.12 M | $53.48 M | $-129,610,000 | $-276,256,000 | $-276,056,000 |
| 2022 | $92.06 M | $70.42 M | $-220,539,000 | $-364,983,000 | $-368,198,000 |
| 2021 | $101.91 M | $77.01 M | $-453,798,000 | $-523,280,000 | $-523,837,000 |
| 2020 | $152.92 M | $133.44 M | $-347,458,000 | $-443,947,000 | $-444,440,000 |
| 2019 | $114.62 M | $93.24 M | $-380,544,000 | $-440,054,000 | $-440,667,000 |
| 2018 | $1.19 B | $1.17 B | $736.37 M | $682.73 M | $681.31 M |
| 2017 | $307.71 M | $277.16 M | $-24,400,000 | $-96,076,000 | $-96,692,000 |
| 2016 | $165.44 M | $135.22 M | $-95,117,000 | $-152,648,000 | $-153,524,000 |
| 2015 | $230.78 M | $196.68 M | $-14,836,000 | $-80,671,000 | $-81,177,000 |
| 2014 | $200.71 M | $172.17 M | $-2,744,000 | $-54,428,000 | $-53,916,000 |
| 2013 | $148.92 M | $110.41 M | $-104,731,000 | $-159,768,000 | $-162,013,000 |
| 2012 | $81.19 M | $50.76 M | $-121,720,000 | $-171,449,000 | $-171,855,000 |
| 2011 | $71.48 M | $49.59 M | $-106,742,000 | $-132,960,000 | $-133,978,000 |
| 2010 | $159.04 M | $133.37 M | $2.42 M | $-37,057,000 | $-37,938,000 |
| 2009 | $71.93 M | $40.98 M | $-76,563,000 | $-102,772,000 | $-102,519,000 |
| 2008 | $90.19 M | $55.15 M | $-178,484,000 | $35.14 M | $-34,336,000 |
| 2007 | $273.03 M | $125.51 M | $-58,326,000 | $-31,452,000 | $-32,761,000 |
| 2006 | $217.72 M | $99.63 M | $-101,578,000 | $-153,933,000 | $-154,761,000 |
| 2005 | $126.28 M | $90.28 M | $-73,792,000 | $-185,248,000 | $-185,111,000 |
| 2004 | $114.27 M | $94.47 M | $-45,793,000 | $-102,049,000 | $-101,886,000 |
| 2003 | $106.26 M | $91.58 M | $-79,977,000 | $-46,513,000 | $-46,682,000 |
| 2002 | $94.85 M | $87.83 M | $-80,116,000 | $-107,468,000 | $-107,468,000 |
| 2001 | $77.47 M | $73.3 M | $80.14 M | $-250,008,000 | $-250,008,000 |
| 2000 | $51.63 M | $51.63 M | $-11,739,000 | $-97,403,000 | $-97,403,000 |
| 1999 | $41.36 M | $41.36 M | $-13,450,000 | $-50,374,000 | $-38,448,000 |
| 1998 | $21.8 M | $21.8 M | $-18,392,000 | $ | $-18,356,000 |
| 1997 | $16.25 M | $16.25 M | $-11,286,000 | $ | $-9,983,000 |
| 1996 | $6.9 M | $8.1 M | $-11,900,000 | $-9,900,000 | $-10,000,000 |
| 1995 | $3.4 M | $4.5 M | $-9,000,000 | $-7,500,000 | $-7,700,000 |
| 1994 | $1.7 M | $2.2 M | $-5,800,000 | $-5,100,000 | $-5,300,000 |